Pharmafile Logo
Pharmafocus logo
Advanced Search

Enzymatica appoints Sana Alajmovic as new CEO

August 12, 2025
Research and Development Corporate, Enzymatica, Infections and infestations

The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …

Appointment
bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025
Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …

News

Sanner appoints new CEO to drive CDMO strategy

August 11, 2025
Contract Manufacturing, Manufacturing and Production CEO, Corporate, Sanner, contract development and manufacturing organisation

German packaging solutions company, Sanner, has announced a significant leadership change as it advances its transformation into a contract development …

Appointment
640px-eye_iris

NICE recommends treatment for rare genetic eye disorder

August 11, 2025
Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …

News

ARTBIO expands board and establishes technical advisory board

August 11, 2025
Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …

Appointment
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025
Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …

News
az_vaccine

Rollout of world-first gonorrhoea vaccine programme begins under NHS

August 8, 2025
Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination

From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …

News

Horus Pharma expands distribution in North Africa and the Middle East

August 8, 2025
Mergers and Acquisitions, Research and Development Corporate, Horus Pharma, Opthalmology, distribution agreement

Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries …

News

Aragen appoints Aniel Khubchandani as CEO of development and manufacturing solutions division

August 8, 2025
Manufacturing Services, Manufacturing and Production Aragen Life Sciences, CEO, Corporate, development and manufacturing solutions, manufacturing services

Aragen Life Sciences, based in Hyderabad, India, has appointed Aniel Khubchandani as CEO of its development and manufacturing solutions (DMS) …

Appointment
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025
Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …

News
hospital

Sanome’s AI tool gains certification for early detection of hospital infections

August 7, 2025
Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections

Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …

News
computer_doctor

Cognizant launches tool to support secure AI integration in healthcare platforms

August 7, 2025
Business Services, Technical Consultancy Cognizant, Devices, healthcare software

US tech solutions company, Cognizant, has launched TriZetto AI Gateway, a new tool designed to embed generative AI functions across …

News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025
Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …

News

MedaSystems appoints Anton White as vice president of growth

August 6, 2025
Business Services Corporate, MedaSystems, vice president of growth

US software solutions company, MedaSystems, has named Anton White as vice president of growth to lead global go-to-market strategy and …

Appointment
lungs

M42 study highlights positive performance of AI model for tuberculosis screening

August 6, 2025
Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis

Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …

News
sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

News
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025
Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …

News
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025
Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …

News

Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease

August 5, 2025
Mergers and Acquisitions Corporate, Crohn’s disease, Fresenius Kabi, Gastrointestinal tract, Polpharma Biologics, ulcerative colitis

Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to …

News

Freya Pharma launches phase 2 study of therapy for female sexual dysfunction

August 5, 2025
Research and Development Female Sexual Interest/Arousal Disorder (FSIAD), Freya Pharma Solutions, Genito-Urinary system, sexual health

Freya Pharma Solutions has announced the initiation of a phase 2 study evaluating its Lybrido to treat female sexual interest/arousal …

News
The Gateway to Local Adoption Series

Latest content

Alto Neuroscience announces new patent for depression treatment

January 15, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026